Narcolepsy: current treatment options

Adult narcolepsy treatment in 2026 still starts with medicines the 2021 AASM hypersomnolence guideline already ranked as STRONG: modafinil, pitolisant, sodium oxybate, and solriamfetol. On 5 August 2026 the FDA approved Orzeyful (oveporexton), the first orexin receptor 2 agonist, for narcolepsy type 1 in adults. It is not lawful to market until the DEA issues a scheduling decision. It is not sitting in a Westerville pharmacy today. This page is a current menu, including that caveat, not a promise that a new tablet is available at the counter.

What does the 2021 AASM guideline still say?

Maski and colleagues published “Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline” in 2021 (J Clin Sleep Med 17(9):1881–1893). For adults with narcolepsy, four recommendations are STRONG versus no treatment: modafinil, pitolisant, sodium oxybate, and solriamfetol. CONDITIONAL suggestions include armodafinil, dextroamphetamine, and methylphenidate. Those comparisons are against no treatment, not against each other. Alphabetical order in the strong list is not a ranking of “best.”

That CPG predates oveporexton. Any conversation that starts and ends with the 2021 paper is incomplete after August 2026. Any conversation that starts with oveporexton and skips the four strong options is also incomplete, because those four are the medicines you can actually fill while DEA scheduling is pending.

Narcolepsy is a neurologic disorder of the sleep-wake cycle. Excessive daytime sleepiness that extra time in bed does not fix is the core feature. Type 1 includes cataplexy and is tied to loss of orexin (hypocretin) signaling. Type 2 does not include cataplexy. Orzeyful’s labeled population is type 1 in adults. Do not extend it to type 2, or to children, from this article. Diagnosis still requires sleep testing, typically nocturnal polysomnography plus a multiple sleep latency test, after other causes of sleepiness have been considered. The narcolepsy condition page covers what the disorder is. This page is what you can be offered for it, and what you cannot pick up yet.

Which wake-promoting medicines are already in use?

Modafinil is a STRONG AASM 2021 recommendation for adult narcolepsy. It is an FDA-approved wake-promoting agent. Armodafinil, the R-enantiomer, is only a CONDITIONAL suggestion in that CPG. Both are daytime medicines for sleepiness. They are not cataplexy drugs. Headache, nausea, and rare serious rashes belong in the counseling conversation; the clinic will use the label, not this paragraph, for that list.

Solriamfetol (Sunosi) is also STRONG in 2021. It is a dopamine-norepinephrine reuptake inhibitor used for excessive daytime sleepiness. It does not treat cataplexy. Blood pressure and heart rate need watching, which is on the product label and is a reason this is a prescribed medicine, not an energy drink with a fancier name.

Pitolisant (Wakix) is STRONG in 2021 and is used for sleepiness and for cataplexy. It is a histamine H3 receptor antagonist/inverse agonist. It is one of the options when someone needs both sleepiness and cataplexy covered without an oxybate. Drug interactions and QT-interval issues are label problems, not blog footnotes. Pediatric age extensions exist in later payer materials; this article is not going to publish an age cutoff that was not re-read from the current Wakix label in this pass.

Older stimulants (methylphenidate, dextroamphetamine) remain CONDITIONAL in the 2021 CPG. They still have U.S. labels for narcolepsy. They are not obsolete, and they are not first in the strong column. If they are already working and tolerated, that is a clinic decision, not an automatic switch because a newer drug was approved.

Where do the oxybates fit?

Sodium oxybate is a STRONG 2021 recommendation for adult narcolepsy. It treats both excessive daytime sleepiness and cataplexy. Immediate-release sodium oxybate (Xyrem and generics) is taken twice nightly. A low-sodium oxybate mixed-salts product (Xywav) is FDA-approved for the same narcolepsy indications in the relevant age groups and also for idiopathic hypersomnia in adults. A once-nightly sodium oxybate (Lumryz) is an FDA-approved option for sleepiness and cataplexy. Maski’s 2021 paper evaluated sodium oxybate as a class against no treatment; it did not rank these brand formulations against each other. Choice among twice-nightly sodium, low-sodium mixed salts, and once-nightly sodium is a label, comorbidity, and logistics conversation (salt load, middle-of-the-night dosing, REMS programs).

Oxybates are central nervous system depressants and controlled substances, dispensed through restricted programs. They are not a casual add-on to a nightcap. Combining them with other sedatives is a safety problem. The existence of three marketed oxybate products does not mean every Ohio plan covers each one. Prior authorization is expected.

What was approved on 5 August 2026, and what is not available yet?

The FDA approved Orzeyful (oveporexton) tablets for narcolepsy type 1 (narcolepsy with cataplexy) in adults. The AASM industry note dated 6 August 2026, based on Takeda’s announcement, describes it as an oral orexin receptor 2 (OX2R) agonist taken twice daily, intended to act on the orexin-signaling deficit that defines type 1 rather than only on individual symptoms. The U.S. prescribing information (Takeda, revised August 2026) matches that indication and the twice-daily schedule.

Because the label was opened for this article, doses can be stated. The recommended dosage is either 1 mg after awakening and 1 mg three to five hours later, or 2 mg after awakening and 2 mg three to five hours later. The maximum recommended total is 4 mg per day. Tablets come in 0.5 mg, 1 mg, and 2 mg strengths. Swallow them whole. Do not split, crush, or chew. They may be taken with or without food, at about the same times each day. If a dose is missed, take the next dose at the next scheduled time; do not double. With moderate CYP3A inhibitors, the label reduces the dose to 0.5 mg after awakening and 0.5 mg three to five hours later (maximum 1 mg per day). Strong CYP3A inhibitors are a contraindication. Avoid strong and moderate CYP3A inducers. Avoid use in severe hepatic impairment (Child-Pugh C) and in severe renal impairment on dialysis; those groups were not studied.

Efficacy came from two randomized, double-blind, placebo-controlled 12-week studies (Study 1, NCT06470828, n=168 randomized; Study 2, NCT06505031, n=105 randomized). The AASM note gives the combined adult NT1 population as 273, which matches 168 plus 105. The primary endpoint in both studies was change from baseline to week 12 in mean sleep latency on the Maintenance of Wakefulness Test. The label reports statistically significant improvements versus placebo on MWT, Epworth Sleepiness Scale, weekly cataplexy rate, the Narcolepsy Severity Scale for Clinical Trials, and patient global impression of change, for the 1 mg and 2 mg twice-daily groups where those arms existed. This article is not going to extract point estimates from a poorly parsed table. The package insert’s Table 3 is the source for magnitudes at the visit.

The most common adverse reactions (incidence at least 5 percent and greater than placebo) are insomnia, pollakiuria (urinary frequency), micturition urgency, and salivary hypersecretion. The label warns that insomnia at initiation may require dose reduction or discontinuation if it lasts beyond seven days and harms daytime function. Screen for lower-urinary-tract symptoms. Report unexplained muscle pain, weakness, or dark urine because of creatine phosphokinase elevations. Safety and effectiveness have not been established under age 18.

The same label and the AASM note state that the drug has been recommended for scheduling under the Controlled Substances Act and will be lawful to market after the DEA issues a scheduling decision. The highlights of prescribing information still read “controlled substance schedule pending.” Takeda’s own communications, as restated in specialty news summaries that cite the PI, say availability is expected after that DEA step. It is therefore not accurate to write that Orzeyful is in the local pharmacy, that a Westerville patient can start it this week, or that Ohio Medicaid or a commercial plan has a listed copay. Ask at the visit whether scheduling has occurred since this page was written. Until then, the 2021 STRONG options are the available pharmacologic backbone.

How should a patient in this office think about the menu?

Sleepiness alone, sleepiness plus cataplexy, disrupted nighttime sleep, shift work, cardiovascular comorbidity, pregnancy plans, and whether someone can take a middle-of-the-night oxybate dose all change the first prescription. Oveporexton, once it is lawful to market, will be a type-1 adult option that targets OX2R. It will not erase the need to confirm the diagnosis. It will not be first-line in type 2 by today’s label. Combining a new OX2R agonist with existing wake-promoting drugs or oxybates is a labeling and interaction problem for the prescriber, not a stack you design from a website.

Dr. Mahmoud Qadoom can review which of the 2021 STRONG medicines you have already tried, whether the diagnosis is type 1 or type 2, and whether oveporexton is even legal to prescribe on the day you sit down. Call (614) 898-9340 during weekday hours. Do not send a symptom narrative through a website form. This page does not replace that visit, and it does not claim that a newly approved tablet is waiting at a Columbus pharmacy.